AI Insight
Two phase 3 randomized controlled trials (REMODEL-1 and REMODEL-2) compared remibrutinib to teriflunomide in patients with relapsing multiple sclerosis. Remibrutinib demonstrated superior efficacy compared to teriflunomide while maintaining a favorable safety profile. The results suggest remibrutinib could serve as a new oral treatment alternative for relapsing multiple sclerosis patients.
Why it matters
These findings could expand treatment options for relapsing multiple sclerosis, a chronic neurological condition affecting millions worldwide. An additional oral therapy with demonstrated superior efficacy and good safety could provide clinicians and patients with more flexibility in managing this debilitating disease.
Understand the Science
Remibrutinib was superior to teriflunomide in patients with relapsing multiple sclerosis, while maintaining a favourable safety profile. These findings support remibrutinib as a potential new oral treatment option for relapsing multiple sclerosis.